Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
January 06, 2025 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Edesa Biotech Reports Fiscal Year 2024 Results
December 13, 2024 16:30 ET
|
Edesa Biotech, Inc.
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
December 09, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 15, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
November 13, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 22, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
October 15, 2024 07:30 ET
|
Molecure
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as...
Hepatitis Treatment Market to hit USD 30.2 billion by 2032, says Global Market Insights Inc.
October 08, 2024 03:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Hepatitis Treatment Market size reached a valuation of USD 22.2 billion in 2023 and is expected to grow at a CAGR of 3.5% through the...
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 02:35 ET
|
Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
October 01, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference